|
Aerosol Therapy for Lung Cancer
|
5R44CA096409-03
|
$371,115
|
$92,779
|
Hansen, Brian
|
AEROPHASE, INC.
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S1
|
$300,000
|
$18,000
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
5U10CA021661-32
|
$8,875,198
|
$532,512
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Community Clinical Oncology Program Research Base
|
5U10CA037422-20
|
$1,483,085
|
$44,493
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group-Statistical Center
|
5U10CA032115-26
|
$1,038,338
|
$62,300
|
Sadek, Ramses
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Drug Delivery Carriers Targeted to Breast Tumor by Fusion Phage Proteins
|
1R01CA125063-01
|
$411,927
|
$102,982
|
PETRENKO, VALERY
|
AUBURN UNIVERSITY AT AUBURN
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-18
|
$480,000
|
$52,800
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
NSABP Participating Sites
|
5U10CA118735-02
|
$66,456
|
$23,260
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer
|
3P50CA058183-13S1
|
$153,479
|
$30,696
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer
|
5P50CA058183-13
|
$2,612,827
|
$522,565
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-24S1
|
$80,000
|
$10,400
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-24
|
$391,000
|
$50,830
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-09
|
$128,678
|
$21,875
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
|
3P50CA105009-04S1
|
$87,500
|
$17,500
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
|
5P50CA105009-04
|
$2,278,757
|
$455,751
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Functional Analysis of Histologic Grade in Breast Cancer
|
5R01CA109325-03
|
$261,573
|
$13,079
|
DAIRKEE, SHANAZ
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
CCOP Research Base, PCPT/PCPT LTFU, and SELECT Programs
|
2U10CA037429-22
|
$14,335,283
|
$1,576,881
|
Coltman, Charles
|
CANCER THERAPY AND RESEARCH CENTER
|
|
Phase I Clinical Trials of Anti-Cancer Agents
|
5U01CA069853-13
|
$501,334
|
$15,040
|
GILES, FRANCIS
|
CANCER THERAPY AND RESEARCH CENTER
|
|
Carle Cancer Center Community Clinical Oncology Program
|
3U10CA035195-24S1
|
$120,000
|
$19,200
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-24
|
$693,116
|
$110,899
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-33
|
$413,938
|
$70,369
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU/UHICC Phase I Trials of Anticancer Agents
|
5U01CA062502-14
|
$560,898
|
$5,609
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-18
|
$5,104,000
|
$102,080
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Molecular Targeting of Bcl-xL Pathway in Cancer
|
5R01CA109181-04
|
$265,033
|
$265,033
|
HALDAR, SUBRATA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cedar Rapids Oncology Project
|
5U10CA052352-18
|
$423,530
|
$55,059
|
WIESENFELD, MARTIN
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
Investigating the Role of Cyr61 in Breast Cancer
|
5R01CA109295-04
|
$303,229
|
$15,161
|
Koeffler, H
|
CEDARS-SINAI MEDICAL CENTER
|
|
Delaware/Christiana Care CCOP
|
2U10CA045418-21
|
$835,003
|
$100,200
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Delaware/Christiana Care CCOP
|
3U10CA045418-21S1
|
$119,011
|
$14,281
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
3U10CA046368-20S1
|
$32,200
|
$6,762
|
MARGOLIN, KIM
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-20
|
$326,504
|
$68,566
|
MARGOLIN, KIM
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Southwest Oncology Group
|
2U10CA004919-48
|
$192,303
|
$40,384
|
BUDD, G
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Southwest Oncology Group
|
3U10CA004919-48S1
|
$25,000
|
$5,250
|
BUDD, G
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
CCOP: Colorado Cancer Research Program
|
2U10CA067753-12
|
$696,877
|
$90,594
|
Pajon, Eduardo
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
Dual Compartmental Targeting of Cancer
|
7R01CA101988-04
|
$223,797
|
$111,899
|
GUSTAFSON, DANIEL
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-11
|
$203,525
|
$101,763
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
Columbus Community Clinical Oncology Program
|
3U10CA035261-24S1
|
$120,000
|
$14,400
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Columbus Community Clinical Oncology Program
|
5U10CA035261-24
|
$641,747
|
$77,010
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Development of Tumor-Targeted Pegylated Colloidal Gold *
|
5R43CA119399-02
|
$249,999
|
$125,000
|
PACIOTTI, GIULIO
|
CYTIMMUNE SCIENCES, INC.
|
|
ECOG Statistical Office
|
5U10CA023318-31
|
$2,367,125
|
$402,411
|
GRAY, ROBERT
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer and Leukemia Group B
|
5U10CA032291-26
|
$333,194
|
$136,610
|
WINER, ERIC
|
DANA-FARBER CANCER INSTITUTE
|
|
Dayton Clinical Oncology Program
|
5U10CA035090-25
|
$864,347
|
$103,722
|
GROSS, HOWARD
|
DAYTON CLINICAL ONCOLOGY PROGRAM
|
|
Central Illinois Community Clinical Oncology Program
|
5U10CA045807-22
|
$1,067,633
|
$170,821
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Eastern Cooperative Oncology Group Chair's Office
|
5U10CA086802-09
|
$644,464
|
$109,559
|
COMIS, ROBERT
|
DREXEL UNIVERSITY
|
|
Cancer and Leukemia Group B
|
5U10CA047577-20
|
$160,142
|
$65,658
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
Cancer and Leukemia Group B Statistical Center
|
5U10CA033601-28
|
$5,064,881
|
$2,076,601
|
GEORGE, STEPHEN
|
DUKE UNIVERSITY
|
|
SPORE IN BREAST CANCER
|
5P50CA068438-10
|
$2,285,265
|
$228,527
|
LYERLY, HERBERT
|
DUKE UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
3U10CA035269-24S1
|
$80,000
|
$7,200
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-24
|
$587,154
|
$52,844
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
Ras/Raf & PI3K/Akt Induced Breast Cancer Drug Resistance
|
5R01CA098195-05
|
$294,304
|
$147,152
|
MC CUBREY, JAMES
|
EAST CAROLINA UNIVERSITY
|
|
Novel anti-melanoma agents and their mechanism of action
|
5R01CA095317-03
|
$257,865
|
$64,466
|
JOSHI, HARISH
|
EMORY UNIVERSITY
|
Total relevant funding to Taxol for this search: $69,346,682
|